Limb-girdle muscular dystrophies: Where next after six decades from the first proposal (Review)

Molecular Medicine Reports

Volumn 9, Issue 5, 2014, Pages 1515-1532

  Mahmood, Omar A ^a,b   Jiang, Xin Mei ^a  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^b UNIVERSITY OF MOSUL   (Iraq)

Author keywords

Diease biomarkers; LGMD; MRI

Indexed keywords

GAMMA INTERFERON; NEUTRALIZING ANTIBODY;

BREATHING MUSCLE; CLINICAL EXAMINATION; DISEASE COURSE; DISEASE MARKER; DISEASE SURVEILLANCE; ELECTRON MICROSCOPY; ELECTROPHYSIOLOGY; GENETIC DISORDER; GENOTYPE PHENOTYPE CORRELATION; HUMAN; IMMUNOHISTOCHEMISTRY; LIMB GIRDLE MUSCULAR DYSTROPHY; LUCIFERASE ASSAY; LUNG FUNCTION; MUSCLE BIOPSY; MUSCLE WEAKNESS; NERVE CONDUCTION; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; PATHOPHYSIOLOGY; PREVALENCE; REVIEW; WESTERN BLOTTING;

ANIMALS; BIOLOGICAL MARKERS; GENETIC ASSOCIATION STUDIES; HUMANS; MUSCULAR DYSTROPHIES, LIMB-GIRDLE; PREVALENCE;

EID: 84899496477     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2048     Document Type: Review

References (174)

1. Danièle N, Richard I and Bartoli M: Ins and outs of therapy in limb girdle muscular dystrophies. Int J Biochem Cell Biol 39: 1608-1624, 2007. (Pubitemid 47090212)
2. Erb W: Dystrophia muscularis progressiva. Dtsch Z Nervenheilkd 1: 13-94, 173-261, 1891 (In German).
3. Leyden E: Klinik Der Rückenmarks-Krankheiten. Vol 2. Hirschwald, Berlin, pp531-540, 1875 (In German).
4. Möbius PJ: Ueber die hereditären nervenkrankheiten. Samml Klin Votr 171. Breitkopf und Härtel, Leipzig, pp1505-1531, 1879 (In German).
5. Bell J: On pseudohypertrophic and allied types of progressive Muscular dystrophy. In: The Treasury of Human Inheritance. Fischer RA (ed). Vol 4. Part 4. Cambridge University Press, London, pp283-342, 1943.
6. Walton JN and Nattrass FJ: On the classification, natural history and treatment of the myopathies. Brain 77: 169-231, 1954.
7. Bushby KM and Gardner-Medwin D: The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. I. Natural history. J Neurol 240: 98-104, 1993. (Pubitemid 23073200)
8. Bushby KM: Diagnostic criteria for the limb-girdle muscular dystrophies: report of the ENMC Consortium on Limb-Girdle Dystrophies. Neuromuscul Disord 5: 71-74, 1995.
9. Hauser MA, Horrigan SK, Salmikangas P, et al: Myotilin is mutated in limb girdle muscular dystrophy 1A. Hum Mol Genet 9: 2141-2147, 2000.
10. Muchir A, Bonne G, van der Kooi AJ, et al: Identification of mutations in the gene encoding lamins A/C in autosomal dominant limb girdle muscular dystrophy with atrioventricular conduction disturbances (LGMD1B). Hum Mol Genet 9: 1453-1459, 2000. (Pubitemid 30312494)
11. Minetti C, Sotgia F, Bruno C, et al: Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy. Nat Genet 18: 365-368, 1998. (Pubitemid 28158166)
12. Greenberg SA, Salajegheh M, Judge DP, et al: Etiology of limb girdle muscular dystrophy 1D/1E determined by laser capture microdissection proteomics. Ann Neurol 71: 141-145, 2012.
13. Harms MB, Sommerville RB, Allred P, et al: Exome sequencing reveals DNAJB6 mutations in dominantly-inherited myopathy. Ann Neurol 71: 407-416, 2012.
14. Sarparanta J, Jonson PH, Golzio C, et al: Mutations affecting the cytoplasmic functions of the co-chaperone DNAJB6 cause limb-girdle muscular dystrophy. Nat Genet 44: 450-455, 2012.
15. Palenzuela L, Andreu AL, Gàmez J, et al: A novel autosomal dominant limb-girdle muscular dystrophy (LGMD 1F) maps to 7q32.1-32.2. Neurology 61: 404-406, 2003. (Pubitemid 36975978)
16. Starling A, Kok F, Passos-Bueno MR, Vainzof M and Zatz M: A new form of autosomal dominant limb-girdle muscular dystrophy (LGMD1G) with progressive fingers and toes flexion limitation maps to chromosome 4p21. Eur J Hum Genet 12: 1033-1040, 2004. (Pubitemid 39610365)
17. Bisceglia L, Zoccolella S, Torraco A, et al: A new locus on 3p23-p25 for an autosomal-dominant limb-girdle muscular dystrophy, LGMD1H. Eur J Hum Genet 18: 636-641, 2010.
18. Richard I, Broux O, Allamand V, et al: Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A. Cell 81: 27-40, 1995.
19. Liu J, Aoki M, Illa I, et al: Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat Genet 20: 31-36, 1998. (Pubitemid 28410339)
20. Noguchi S, McNally EM, Ben Othmane K, et al: Mutations in the dystrophin-associated protein gamma-sarcoglycan in chromosome 13 muscular dystrophy. Science 270: 819-822, 1995.
21. Roberds SL, Leturcq F, Allamand V, et al: Missense mutations in the adhalin gene linked to autosomal recessive muscular dystrophy. Cell 78: 625-633, 1994. (Pubitemid 24268585)
22. Lim LE, Duclos F, Broux O, et al: Beta-sarcoglycan: characterization and role in limb-girdle muscular dystrophy linked to 4q12. Nat Genet 1: 257-265, 1995.
23. Nigro V, de Sá Moreira E, Piluso G, et al: Autosomal recessive limb-girdle muscular dystrophy, LGMD2F, is caused by a mutation in the delta-sarcoglycan gene. Nat Genet 14: 195-198, 1996. (Pubitemid 26338803)
24. Moreira ES, Wiltshire TJ, Faulkner G, et al: Limb-girdle muscular dystrophy type 2G is caused by mutations in the gene encoding the sarcomeric protein telethonin. Nat Genet 24: 163-166, 2000. (Pubitemid 30094717)
25. Frosk P, Weiler T, Nylen E, et al: Limb-girdle muscular dystrophy type 2H associated with mutation in TRIM32, a putative E3-ubiquitin-ligase gene. Am J Hum Genet 70: 663-672, 2002. (Pubitemid 34177921)
26. Brockington M, Yuva Y, Prandini P, et al: Mutations in the fukutin-related protein gene (FKRP) identify limb girdle muscular dystrophy 2I as a milder allelic variant of congenital muscular dystrophy MDC1C. Hum Mol Genet 10: 2851-2859, 2001. (Pubitemid 34030916)
27. Haravuori H, Vihola A, Straub V, et al: Secondary calpain3 deficiency in 2q-linked muscular dystrophy: titin is the candidate gene. Neurology 56: 869-877, 2001. (Pubitemid 32290803)
28. Balci B, Uyanik G, Dincer P, et al: An autosomal recessive limb girdle muscular dystrophy (LGMD2) with mild mental retardation is allelic to Walker-Warburg syndrome (WWS) caused by a mutation in the POMT1 gene. Neuromuscul Disord 15: 271-275, 2005. (Pubitemid 40431931)
29. Bolduc V, Marlow G, Boycott KM, et al: Recessive mutations in the putative calcium-activated chloride channel Anoctamin 5 cause proximal LGMD2L and distal MMD3 muscular dystrophies. Am J Hum Genet 86: 213-221, 2010.
30. Godfrey C, Escolar D, Brockington M, et al: Fukutin gene mutations in steroid-responsive limb girdle muscular dystrophy. Ann Neurol 60: 603-610, 2006. (Pubitemid 44871803)
31. Biancheri R, Falace A, Tessa A, et al: POMT2 gene mutation in limb-girdle muscular dystrophy with inflammatory changes. Biochem Biophys Res Commun 363: 1033-1037, 2007. (Pubitemid 47552963)
32. Clement EM, Godfrey C, Tan J, et al: Mild POMGnT1 mutations underlie a novel limb-girdle muscular dystrophy variant. Arch Neurol 65: 137-141, 2008.
33. Hara Y, Balci-Hayta B, Yoshida-Moriguchi T, et al: A dystroglycan mutation associated with limb-girdle muscular dystrophy. N Engl J Med 364: 939-946, 2011.
34. Nigro V, Aurino S and Piluso G: Limb girdle muscular dystrophies: update on genetic diagnosis and therapeutic approaches. Curr Opin Neurol 24: 429-436, 2011.
35. Gundesli H, Talim B, Korkusuz P, et al: Mutation in exon 1f of PLEC, leading to disruption of plectin isoform 1f, causes autosomal-recessive limb-girdle muscular dystrophy. Am J Hum Genet 87: 834-841, 2010.
36. von Nandelstadh P, Grönholm M, Moza M, Lamberg A, Savilahti H, Carpén O: Actin-organising properties of the muscular dystrophy protein myotilin. Exp Cell Res 310: 131-139, 2005.
37. Maraldi NM, Capanni C, Cenni V, Fini M and Lattanzi G: Laminopathies and lamin-associated signaling pathways. J Cell Biochem 112: 979-992, 2011.
38. Gazzerro E, Sotgia F, Bruno C, Lisanti MP and Minetti C: Caveolinopathies: from the biology of caveolin-3 to human diseases. Eur J Hum Genet 18: 137-145, 2010.
39. Schröder R and Schoser B: Myofibrillar myopathies: a clinical and myopathological guide. Brain Pathol 19: 483-492, 2009.
40. Ojima K, Ono Y, Ottenheijm C, et al: Non-proteolytic functions of calpain-3 in sarcoplasmic reticulum in skeletal muscles. J Mol Biol 407: 439-449, 2011.
41. Ojima K, Kawabata Y, Nakao H, et al: Dynamic distribution of muscle-specific calpain in mice has a key role in physical-stress adaptation and is impaired in muscular dystrophy. J Clin Invest 120: 2672-2683, 2010.
42. Bansal D, Miyake K, Vogel SS, et al: Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature 423: 168-172, 2003. (Pubitemid 36569539)
43. Chen YW, Zhao P, Borup R and Hoffman EP: Expression profiling in the muscular dystrophies: identification of novel aspects of molecular pathophysiology. J Cell Biol 151: 1321-1336, 2000.
44. Zou P, Pinotsis N, Lange S, et al: Palindromic assembly of the giant muscle protein titin in the sarcomeric Z-disk. Nature 439: 229-233, 2006. (Pubitemid 43083147)
45. Shieh PB, Kudryashova E and Spencer MJ: Limb-girdle muscular dystrophy 2H and the role of TRIM32. Handb Clin Neurol 101: 125-133, 2011.
46. Brockington M, Blake DJ, Prandini P, et al: Mutations in the fukutin-related protein gene (FKRP) cause a form of congenital muscular dystrophy with secondary laminin alpha2 deficiency and abnormal glycosylation of alpha-dystroglycan. Am J Hum Genet 69: 1198-1209, 2001. (Pubitemid 33124201)
47. Isralewitz B, Gao M and Schulten K: Steered molecular dynamics and mechanical functions of proteins. Curr Opin Struct Biol 11: 224-230, 2001. (Pubitemid 32289426)
48. Akasaka-Manya K, Manya H, Nakajima A, Kawakita M and Endo T: Physical and functional association of human protein O-mannosyltransferases 1 and 2. J Biol Chem 281: 19339-19345, 2006. (Pubitemid 44035439)
49. Yamamoto T, Shibata N, Saito Y, Osawa M and Kobayashi M: Functions of fukutin, a gene responsible for Fukuyama type congenital muscular dystrophy, in neuromuscular system and other somatic organs. Cent Nerv Syst Agents Med Chem 10: 169-179, 2010.
50. Yoshida A, Kobayashi K, Manya H, et al: Muscular dystrophy and neuronal migration disorder caused by mutations in a glycosyltransferase, POMGnT1. Dev Cell 1: 717-724, 2001. (Pubitemid 33586123)
51. Barresi R and Campbell KP: Dystroglycan: from biosynthesis to pathogenesis of human disease. J Cell Sci 119: 199-207, 2006. (Pubitemid 43210689)
52. Moza M, Mologni L, Trokovic R, Faulkner G, Partanen J and Carpén O: Targeted deletion of the muscular dystrophy gene myotilin does not perturb muscle structure or function in mice. Mol Cell Biol 27: 244-252, 2007. (Pubitemid 46013248)
53. Garvey SM, Liu Y, Miller SE and Hauser MA: Myotilin overexpression enhances myopathology in the LGMD1A mouse model. Muscle Nerve 37: 663-667, 2008. (Pubitemid 351590559)
54. Muchir A, Shan J, Bonne G, Lehnart SE and Worman HJ: Inhibition of extracellular signal-regulated kinase signaling to prevent cardiomyopathy caused by mutation in the gene encoding A-type lamins. Hum Mol Genet 18: 241-247, 2009.
55. Kawakami E, Kinouchi N, Adachi T, et al: Atelocollagen-mediated systemic administration of myostatin-targeting siRNA improves muscular atrophy in caveolin-3-deficient mice. Dev Growth Differ 53: 48-54, 2011.
56. Bartoli M, Poupiot J, Vulin A, et al: AAV-mediated delivery of a mutated myostatin propeptide ameliorates calpain 3 but not alpha-sarcoglycan deficiency. Gene Ther 14: 733-740, 2007. (Pubitemid 46585654)
57. Han R, Frett EM, Levy JR, et al: Genetic ablation of complement C3 attenuates muscle pathology in dysferlin-deficient mice. J Clin Invest 120: 4366-4374, 2010.
58. Gallardo E, Rojas-García R, de Luna N, Pou A, Brown RH Jr. and Illa I: Inflammation in dysferlin myopathy: immunohistochemical characterization of 13 patients. Neurology 57: 2136-2138, 2001. (Pubitemid 33126892)
59. Ohsawa Y, Okada T, Nishimatsu S, et al: An inhibitor of transforming growth factor beta type I receptor ameliorates muscle atrophy in a mouse model of caveolin 3-deficient muscular dystrophy. Lab Invest 92: 1100-1114, 2012.
60. Bartoli M, Roudaut C, Martin S, et al: Safety and efficacy of AAV-mediated calpain 3 gene transfer in a mouse model of limb-girdle muscular dystrophy type 2A. Mol Ther 13: 250-259, 2006. (Pubitemid 43056890)
61. Albrecht DE, Rufibach LE, Williams BA, Monnier N, Hwang E and Mittal P: 5th Annual Dysferlin Conference 11-14 July 2011, Chicago, Illinois, USA. Neuromuscul Disord 22: 471-477, 2012.
62. Albrecht DE, Garg N, Rufibach LE, et al: 3rd Annual Dysferlin Conference 2-5 June 2009, Boston, Massachusetts, USA. Neuromuscul Disord 19: 867-873, 2009.
63. Lostal W, Bartoli M, Bourg N, et al: Efficient recovery of dysferlin deficiency by dual adeno-associated vector-mediated gene transfer. Hum Mol Genet 19: 1897-1907, 2010.
64. Kong KY, Ren J, Kraus M, Finklestein SP and Brown RH Jr.: Human umbilical cord blood cells differentiate into muscle in sjl muscular dystrophy mice. Stem Cells 22: 981-993, 2004. (Pubitemid 39507085)
65. Potgieter M, Pretorius E, Van der Merwe CF, et al: Histological assessment of SJL/J mice treated with the antioxidants coenzyme Q10 and resveratrol. Micron 42: 275-282, 2011.
66. Cordier L, Hack AA, Scott MO, et al: Rescue of skeletal muscles of gamma-sarcoglycan-deficient mice with adeno-associated virus-mediated gene transfer. Mol Ther 1: 119-129, 2000.
67. Bogdanovich S, McNally EM and Khurana TS: Myostatin blockade improves function but not histopathology in a murine model of limb-girdle muscular dystrophy 2C. Muscle Nerve 37: 308-316, 2008. (Pubitemid 351304790)
68. Allikian MJ, Hack AA, Mewborn S, Mayer U and McNally EM: Genetic compensation for sarcoglycan loss by integrin alpha7beta1 in muscle. J Cell Sci 117: 3821-3830, 2004. (Pubitemid 39207320)
69. Allamand V, Donahue KM, Straub V, Davisson RL, Davidson BL and Campbell KP: Early adenovirus-mediated gene transfer effectively prevents muscular dystrophy in alpha-sarcoglycan-deficient mice. Gene Ther 7: 1385-1391, 2000. (Pubitemid 30662244)
70. Galvez BG, Sampaolesi M, Brunelli S, et al: Complete repair of dystrophic skeletal muscle by mesoangioblasts with enhanced migration ability. J Cell Biol 174: 231-243, 2006. (Pubitemid 44079858)
71. Minetti GC, Colussi C, Adami R, et al: Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors. Nat Med 12: 1147-1150, 2006. (Pubitemid 44527349)
72. Dressman D, Araishi K, Imamura M, et al: Delivery of alpha- and beta-sarcoglycan by recombinant adeno-associated virus: efficient rescue of muscle, but differential toxicity. Hum Gene Ther 13: 1631-1646, 2002. (Pubitemid 35034683)
73. Hoshijima M, Hayashi T, Jeon YE, et al: Delta-sarcoglycan gene therapy halts progression of cardiac dysfunction, improves respiratory failure, and prolongs life in myopathic hamsters. Circ Heart Fail 4: 89-97, 2011.
74. Iwata Y, Katanosaka Y, Shijun Z, et al: Protective effects of Ca2+ handling drugs against abnormal Ca2+ homeostasis and cell damage in myopathic skeletal muscle cells. Biochem Pharmacol 70: 740-751, 2005. (Pubitemid 41058709)
75. Zhu T, Zhou L, Mori S, et al: Sustained whole-body functional rescue in congestive heart failure and muscular dystrophy hamsters by systemic gene transfer. Circulation 112: 2650-2659, 2005. (Pubitemid 41532602)
76. Henning RJ, Aufman J, Shariff M, et al: Human umbilical cord blood mononuclear cells decrease fibrosis and increase cardiac function in cardiomyopathy. Regen Med 5: 45-54, 2010.
77. Lapidos KA, Chen YE, Earley JU, et al: Transplanted hematopoietic stem cells demonstrate impaired sarcoglycan expression after engraftment into cardiac and skeletal muscle. J Clin Invest 114: 1577-1585, 2004. (Pubitemid 40385548)
78. Nomura T, Ashihara E, Tateishi K, et al: Skeletal myosphere-derived progenitor cell transplantation promotes neovascularization in delta-sarcoglycan knockdown cardiomyopathy. Biochem Biophys Res Commun 352: 668-674, 2007. (Pubitemid 44880306)
79. Parsons SA, Millay DP, Sargent MA, McNally EM and Molkentin JD: Age-dependent effect of myostatin blockade on disease severity in a murine model of limb-girdle muscular dystrophy. Am J Pathol 168: 1975-1985, 2006. (Pubitemid 43825317)
80. Goehringer C, Rutschow D, Bauer R, et al: Prevention of cardiomyopathy in delta-sarcoglycan knockout mice after systemic transfer of targeted adeno-associated viral vectors. Cardiovasc Res 82: 404-410, 2009.
81. Charton K, Danièle N, Vihola A, et al: Removal of the calpain 3 protease reverses the myopathology in a mouse model for titinopathies. Hum Mol Genet 19: 4608-4624, 2010.
82. Barresi R, Michele DE, Kanagawa M, et al: LARGE can functionally bypass alpha-dystroglycan glycosylation defects in distinct congenital muscular dystrophies. Nat Med 10: 696-703, 2004. (Pubitemid 38937634)
83. Straub V, Donahue KM, Allamand V, Davisson RL, Kim YR and Campbell KP: Contrast agent-enhanced magnetic resonance imaging of skeletal muscle damage in animal models of muscular dystrophy. Magn Reson Med 44: 655-659, 2000.
84. Bartoli M, Poupiot J, Goyenvalle A, et al: Noninvasive monitoring of therapeutic gene transfer in animal models of muscular dystrophies. Gene Ther 13: 20-28, 2006. (Pubitemid 41823848)
85. Mendell JR, Rodino-Klapac LR, Rosales XQ, et al: Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D. Ann Neurol 68: 629-638, 2010.
86. Norwood FL, Harling C, Chinnery PF, Eagle M, Bushby K and Straub V: Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population. Brain 132: 3175-3186, 2009.
87. Gómez-Díaz B, Rosas-Vargas H, Roque-Ramírez B, et al: Immunodetection analysis of muscular dystrophies in Mexico. Muscle Nerve 45: 338-345, 2012.
88. Diniz G, Eryaşar G, Türe S, et al: A regional panorama of dysferlinopathies. Turk Patoloji Derg 28: 259-265, 2012.
89. Magri F, Bo RD, D'Angelo MG, et al: Frequency and characterisation of anoctamin 5 mutations in a cohort of Italian limb-girdle muscular dystrophy patients. Neuromuscul Disord 22: 934-943, 2012.
90. Guglieri M, Magri F, D'Angelo MG, et al: Clinical, molecular, and protein correlations in a large sample of genetically diagnosed Italian limb girdle muscular dystrophy patients. Hum Mutat 29: 258-266, 2008. (Pubitemid 351240598)
91. Fanin M, Nascimbeni AC, Aurino S, et al: Frequency of LGMD gene mutations in Italian patients with distinct clinical phenotypes. Neurology 72: 1432-1435, 2009.
92. Urtasun M, Sáenz A, Roudaut C, et al: Limb-girdle muscular dystrophy in Guipúzcoa (Basque Country, Spain). Brain 121: 1735-1747, 1998. (Pubitemid 28419978)
93. Walter MC, Petersen JA, Stucka R, et al: FKRP (826C>A) frequently causes limb-girdle muscular dystrophy in German patients. J Med Genet 41: e50, 2004.
94. Hicks D, Sarkozy A, Muelas N, et al: A founder mutation in Anoctamin 5 is a major cause of limb-girdle muscular dystrophy. Brain 134: 171-182, 2011.
95. Stensland E, Lindal S, Jonsrud C, et al: Prevalence, mutation spectrum and phenotypic variability in Norwegian patients with Limb Girdle Muscular Dystrophy 2I. Neuromuscul Disord 21: 41-46, 2011.
96. Sveen ML, Schwartz M and Vissing J: High prevalence and phenotype-genotype correlations of limb girdle muscular dystrophy type 2I in Denmark. Ann Neurol 59: 808-815, 2006. (Pubitemid 43673158)
97. Penttila S, Palmio J, Suominen T, et al: Eight new mutations and the expanding phenotype variability in muscular dystrophy caused by ANO5. Neurology 78: 897-903, 2012.
98. Lo HP, Cooper ST, Evesson FJ, et al: Limb-girdle muscular dystrophy: diagnostic evaluation, frequency and clues to pathogenesis. Neuromuscul Disord 18: 34-44, 2008. (Pubitemid 351181397)
99. Moore SA, Shilling CJ, Westra S, et al: Limb-girdle muscular dystrophy in the United States. J Neuropathol Exp Neurol 65: 995-1003, 2006. (Pubitemid 44521800)
100. Dinçer P P, Leturcq F, Richard I, et al: A biochemical, genetic, and clinical survey of autosomal recessive limb girdle muscular dystrophies in Turkey. Ann Neurol 42: 222-229, 1997. (Pubitemid 27340468)
101. Pogoda TV, Krakhmaleva IN, Lipatova NA, Shakhovskaya NI, Shishkin SS and Limborska SA: High incidence of 550delA mutation of CAPN3 in LGMD2 patients from Russia. Hum Mutat 15: 295, 2000.
102. Zatz M, de Paula F, Starling A and Vainzof M: The 10 autosomal recessive limb-girdle muscular dystrophies. Neuromuscul Disord 13: 532-544, 2003. (Pubitemid 36961342)
103. Chae J, Minami N, Jin Y, et al: Calpain 3 gene mutations: genetic and clinico-pathologic findings in limb-girdle muscular dystrophy. Neuromuscul Disord 11: 547-555, 2001. (Pubitemid 32761798)
104. Hayashi S, Ohsawa Y, Takahashi T, et al: Rapid screening for Japanese dysferlinopathy by fluorescent primer extension. Intern Med 49: 2693-2696, 2010.
105. Meena AK, Sreenivas D, Sundaram C, et al: Sarcoglycanopathies: a clinico-pathological study. Neurol India 55: 117-121, 2007. (Pubitemid 46918478)
106. Pathak P, Sharma MC, Sarkar C, et al: Limb girdle muscular dystrophy type 2A in India: a study based on semi-quantitative protein analysis, with clinical and histopathological correlation. Neurol India 58: 549-554, 2010.
107. Gayathri N, Alefia R, Nalini A, et al: Dysferlinopathy: spectrum of pathological changes in skeletal muscle tissue. Indian J Pathol Microbiol 54: 350-354, 2011.
108. Hadj Salem I, Kamoun F, Louhichi N, Trigui M, Triki C and Fakhfakh F: Impact of single-nucleotide polymorphisms at the TP53-binding and responsive promoter region of BCL2 gene in modulating the phenotypic variability of LGMD2C patients. Mol Biol Rep 39: 7479-7486, 2012.
109. Sinnreich M, Therrien C and Karpati G: Lariat branch point mutation in the dysferlin gene with mild limb-girdle muscular dystrophy. Neurology 66: 1114-1116, 2006. (Pubitemid 44044807)
110. Tagawa K, Ogawa M, Kawabe K, et al: Protein and gene analyses of dysferlinopathy in a large group of Japanese muscular dystrophy patients. J Neurol Sci 211: 23-28, 2003. (Pubitemid 36593263)
111. Takahashi T, Aoki M, Tateyama M, et al: Dysferlin mutations in Japanese Miyoshi myopathy: relationship to phenotype. Neurology 60: 1799-1804, 2003. (Pubitemid 36737077)
112. Nagashima T, Chuma T, Mano Y, et al: Dysferlinopathy associated with rigid spine syndrome. Neuropathology 24: 341-346, 2004. (Pubitemid 39664759)
113. Saccone V, Palmieri M, Passamano L, et al: Mutations that impair interaction properties of TRIM32 associated with limb-girdle muscular dystrophy 2H. Hum Mutat 29: 240-247, 2008. (Pubitemid 351240596)
114. Kondo-lida E, Kobayashi K, Watanabe M, et al: Novel mutations and genotype-phenotype relationships in 107 families with Fukuyama-type congenital muscular dystrophy (FCMD). Hum Mol Genet 8: 2303-2309, 1999. (Pubitemid 29525346)
115. Scharner J, Gnocchi VF, Ellis JA and Zammit PS: Genotype-phenotype correlations in laminopathies: how does fate translate? Biochem Soc Trans 38: 257-262, 2010.
116. Zhang Y, Ye J, Chen D, et al: Differential expression profiling between the relative normal and dystrophic muscle tissues from the same LGMD patient. J Transl Med 4: 53, 2006.
117. Godfrey C, Clement E, Mein R, et al: Refining genotype phenotype correlations in muscular dystrophies with defective glycosylation of dystroglycan. Brain 130: 2725-2735, 2007. (Pubitemid 47511718)
118. Klinge L, Dean AF, Kress W, et al: Late onset in dysferlinopathy widens the clinical spectrum. Neuromuscul Disord 18: 288-290, 2008.
119. Rosales XQ, Gastier-Foster JM, Lewis S, et al: Novel diagnostic features of dysferlinopathies. Muscle Nerve 42: 14-21, 2010.
120. Broglio L, Tentorio M, Cotelli MS, et al: Limb-girdle muscular dystrophy-associated protein diseases. Neurologist 16: 340-352, 2010.
121. Mercuri E, Brockington M, Straub V, et al: Phenotypic spectrum associated with mutations in the fukutin-related protein gene. Ann Neurol 53: 537-542, 2003. (Pubitemid 36373268)
122. Gáti I, Danielsson O, Gunnarsson C, et al: Bent spine syndrome: a phenotype of dysferlinopathy or a symptomatic DYSF gene mutation carrier. Eur Neurol 67: 300-302, 2012.
123. Hermans MC, Pinto YM, Merkies IS, de Die-Smulders CE, Crijns HJ and Faber CG: Hereditary muscular dystrophies and the heart. Neuromuscul Disord 20: 479-492, 2010.
124. Filosto M, Tonin P, Vattemi G, et al: Chronic ophthalmoparesis in limb girdle muscular dystrophy 1C. J Neurol Neurosurg Psychiatry 80: 448-449, 2009.
125. Selcen D: Myofibrillar myopathies. Neuromuscul Disord 21: 161-171, 2011.
126. Palmieri A, Manara R, Bello L, et al: Cognitive profile and MRI findings in limb-girdle muscular dystrophy 2I. J Neurol 258: 1312-1320, 2011.
127. Zhang Y, Huang JJ, Wang ZQ, Wang N and Wu ZY: Value of muscle enzyme measurement in evaluating different neuromuscular diseases. Clin Chim Acta 413: 520-524, 2012.
128. Wattjes MP, Kley RA and Fischer D: Neuromuscular imaging in inherited muscle diseases. Eur Radiol 20: 2447-2460, 2010.
129. Fischer D, Walter MC, Kesper K, et al: Diagnostic value of muscle MRI in differentiating LGMD2I from other LGMDs. J Neurol 252: 538-547, 2005. (Pubitemid 40768169)
130. Fischer D, Kley RA, Strach K, et al: Distinct muscle imaging patterns in myofibrillar myopathies. Neurology 71: 758-765, 2008.
131. Starling A, de Paula F, Silva H, Vainzof M and Zatz M: Calpainopathy: how broad is the spectrum of clinical variability? J Mol Neurosci 21: 233-236, 2003. (Pubitemid 39117973)
132. Santoro L, Nolano M, Faraso S, et al: Perioral skin biopsy to study skeletal muscle protein expression. Muscle Nerve 41: 392-398, 2010.
133. Nagaraju K, Rawat R, Veszelovszky E, et al: Dysferlin deficiency enhances monocyte phagocytosis: a model for the inflammatory onset of limb-girdle muscular dystrophy 2B. Am J Pathol 172: 774-785, 2008. (Pubitemid 351354549)
134. Brown RH Jr. and Amato A: Calpainopathy and eosinophilic myositis. Ann Neurol 59: 875-877, 2006.
135. Baumeister SK, Todorovic S, Milić-Rasić V, Dekomien G, Lochmüller H, Walter MC: Eosinophilic myositis as presenting symptom in gamma-sarcoglycanopathy. Neuromuscul Disord 19: 167-171, 2009.
136. Vinit J, Samson M, Jr., Gaultier JB, et al: Dysferlin deficiency treated like refractory polymyositis. Clin Rheumatol 29: 103-106, 2010.
137. Claeys KG, Fardeau M, Schröder R, et al: Electron microscopy in myofibrillar myopathies reveals clues to the mutated gene. Neuromuscul Disord 18: 656-666, 2008.
138. Cacciottolo M, Numitone G, Aurino S, et al: Muscular dystrophy with marked Dysferlin deficiency is consistently caused by primary dysferlin gene mutations. Eur J Hum Genet 19: 974-980, 2011.
139. Trabelsi M, Kavian N, Daoud F, et al: Revised spectrum of mutations in sarcoglycanopathies. Eur J Hum Genet 16: 793-803, 2008. (Pubitemid 351865677)
140. Herrmann R, Straub V, Blank M, et al: Dissociation of the dystroglycan complex in caveolin-3-deficient limb girdle muscular dystrophy. Hum Mol Genet 9: 2335-2340, 2000.
141. Vainzof M, Moreira ES, Suzuki OT, et al: Telethonin protein expression in neuromuscular disorders. Biochim Biophys Acta 1588: 33-40, 2002.
142. Charlton R, Henderson M, Richards J, et al: Immunohistochemical analysis of calpain 3: advantages and limitations in diagnosing LGMD2A. Neuromuscul Disord 19: 449-457, 2009.
143. Fanin M, Nascimbeni AC, Fulizio L, Trevisan CP, Meznaric-Petrusa M and Angelini C: Loss of calpain-3 auto-catalytic activity in LGMD2A patients with normal protein expression. Am J Pathol 163: 1929-1936, 2003. (Pubitemid 37310023)
144. Fanin M, Nascimbeni AC, Tasca E and Angelini C: How to tackle the diagnosis of limb-girdle muscular dystrophy 2A. Eur J Hum Genet 17: 598-603, 2009.
145. Sáenz A, Leturcq F, Cobo AM, et al: LGMD2A: genotype-phenotype correlations based on a large mutational survey on the calpain 3 gene. Brain 128: 732-742, 2005. (Pubitemid 40516912)
146. Groen EJ, Charlton R, Barresi R, et al: Analysis of the UK diagnostic strategy for limb girdle muscular dystrophy 2A. Brain 130: 3237-3249, 2007. (Pubitemid 350209076)
147. Fanin M, Fulizio L, Nascimbeni AC, et al: Molecular diagnosis in LGMD2A: mutation analysis or protein testing? Hum Mutat 24: 52-62, 2004. (Pubitemid 38859224)
148. Hackman P, Vihola A, Haravuori H, et al: Tibial muscular dystrophy is a titinopathy caused by mutations in TTN, the gene encoding the giant skeletal-muscle protein titin. Am J Hum Genet 71: 492-500, 2002. (Pubitemid 34970121)
149. Borg K, Stucka R, Locke M, et al: Intragenic deletion of TRIM32 in compound heterozygotes with sarcotubular myopathy/LGMD2H. Hum Mutat 30: E831-844, 2009.
150. Sewry CA: Muscular dystrophies: an update on pathology and diagnosis. Acta Neuropathol 120: 343-358, 2010.
151. Ho M, Gallardo E, McKenna-Yasek D, De Luna N, Illa I and Brown Jr RH: A novel, blood-based diagnostic assay for limb girdle muscular dystrophy 2B and Miyoshi myopathy. Ann Neurol 51: 129-133, 2002. (Pubitemid 34027987)
152. Escher C, Lochmüller H, Fischer D, et al: Reverse protein arrays as novel approach for protein quantification in muscular dystrophies. Neuromuscul Disord 20: 302-309, 2010.
153. Blázquez L, Azpitarte M, Sáenz A, et al: Characterization of novel CAPN3 isoforms in white blood cells: an alternative approach for limb-girdle muscular dystrophy 2A diagnosis. Neurogenetics 9: 173-182, 2008.
154. De Luna N, Freixas A, Gallano P, et al: Dysferlin expression in monocytes: a source of mRNA for mutation analysis. Neuromuscul Disord 17: 69-76, 2007. (Pubitemid 46186004)
155. Teer JK and Mullikin JC: Exome sequencing: the sweet spot before whole genomes. Hum Mol Genet 19: R145-151, 2010.
156. Balci B, Aurino S, Haliloglu G, et al: Calpain-3 mutations in Turkey. Eur J Pediatr 165: 293-298, 2006.
157. Fanin M, Nascimbeni AC, Fulizio L and Angelini C: The frequency of limb girdle muscular dystrophy 2A in northeastern Italy. Neuromuscul Disord 15: 218-224, 2005. (Pubitemid 40255777)
158. Takahashi T, Aoki M, Suzuki N, et al: Clinical features and a mutation with late onset of limb girdle muscular dystrophy 2B. J Neurol Neurosurg Psychiatry 84: 433-440, 2012.
159. Park YE, Kim HS, Lee CH, Nam TS, Choi YC and Kim DS: Two common mutations (p.Gln832X and c.663+1G>C) account for about a third of the DYSF mutations in Korean patients with dysferlinopathy. Neuromuscul Disord 22: 505-510, 2012.
160. Barthélémy F, Wein N, Krahn M, Lévy N, Bartoli M.: Translational research and therapeutic perspectives in dysferlinopathies. Mol Med 17: 875-882, 2011.
161. Hackman P, Juvonen V, Sarparanta J, et al: Enrichment of the R77C alpha-sarcoglycan gene mutation in Finnish LGMD2D patients. Muscle Nerve 31: 199-204, 2005. (Pubitemid 40189841)
162. Schoser BG, Frosk P, Engel AG, Klutzny U, Lochmüller H and Wrogemann K: Commonality of TRIM32 mutation in causing sarcotubular myopathy and LGMD2H. Ann Neurol 57: 591-595, 2005. (Pubitemid 40471176)
163. Kang PB, Feener CA, Estrella E, et al: LGMD2I in a North American population. BMC Musculoskelet Disord 8: 115, 2007.
164. Norwood F, de Visser M, Eymard B, Lochmüller H and Bushby K; EFNS Guideline Task Force: EFNS guideline on diagnosis and management of limb girdle muscular dystrophies. Eur J Neurol 14: 1305-1312, 2007. (Pubitemid 350135303)
165. Eagle M: Report on the muscular dystrophy campaign workshop: exercise in neuromuscular diseases Newcastle, January 2002. Neuromuscul Disord 12: 975-983, 2002.
166. Miladi N, Bourguignon JP and Hentati F: Cognitive and psychological profile of a Tunisian population of limb girdle muscular dystrophy. Neuromuscul Disord 9: 352-354, 1999. (Pubitemid 29301719)
167. Wagner KR, Fleckenstein JL, Amato AA, et al: A phase I/II trial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol 63: 561-571, 2008.
168. Lerario A, Cogiamanian F, Marchesi C, et al: Effects of rituximab in two patients with dysferlin-deficient muscular dystrophy. BMC Musculoskelet Disord 11: 157, 2010.
169. Hattori H, Nagata E, Oya Y, et al: A novel compound heterozygous dysferlin mutation in Miyoshi myopathy siblings responding to dantrolene. Eur J Neurol 14: 1288-1291, 2007. (Pubitemid 47621956)
170. Luna ND, Díaz-Manera J, Paradas C, et al: 1α, 25(OH)(2)-Vitamin D3 increases dysferlin expression in vitro and in a human clinical trial. Mol Ther 20: 1988-1997, 2012.
171. Walter MC, Reilich P, Thiele S, et al: Treatment of dysferlinopathy with deflazacort: a double-blind, placebo-controlled clinical trial. Orphanet J Rare Dis 8: 26, 2013.
172. Angelini C, Fanin M, Menegazzo E, Freda MP, Duggan DJ and Hoffman EP: Homozygous alpha-sarcoglycan mutation in two siblings: one asymptomatic and one steroid-responsive mild limb-girdle muscular dystrophy patient. Muscle Nerve 21: 769-775, 1998. (Pubitemid 28248682)
173. Darin N, Kroksmark AK, Ahlander AC, Moslemi AR, Oldfors A and Tulinius M: Inflammation and response to steroid treatment in limb-girdle muscular dystrophy 2I. Eur J Paediatr Neurol 11: 353-357, 2007. (Pubitemid 47534996)
174. Walter MC, Lochmüller H, Reilich P, et al: Creatine monohydrate in muscular dystrophies: A double-blind, placebo-controlled clinical study. Neurology 54: 1848-1850, 2000. (Pubitemid 30428416)